NCT05008393View on ClinicalTrials.gov

Efficacy of PJS-539 for Adult Patients With COVID-19.

PHASE2CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

September 25, 2021

Primary Completion Date

February 3, 2022

Study Completion Date

March 4, 2022

Conditions
Covid19COVID-19 Pneumonia
Interventions
DRUG

PJS-539 Dose 1

Patients will receive PJS-539 dose 1 daily for 10 days.

DRUG

PJS-539 Dose 2

Patients will receive PJS-539 Dose 2 daily for 10 days.

DRUG

Placebo

Patients will receive placebo daily for 10 days.

Trial Locations (1)

04005-000

Hospital do Coracao, São Paulo

Sponsors

Collaborators (1)

Covicept
All Listed Sponsors
collaborator

Covicept

UNKNOWN

lead

Hospital do Coracao

OTHER

NCT05008393 - Efficacy of PJS-539 for Adult Patients With COVID-19. | Biotech Hunter | Biotech Hunter